Ingevity Corp
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Inventories, net
Note 6: Inventories, net
| December 31, | ||
|---|---|---|
| In millions | 2025 | 2024 |
| Raw materials | $45.7 | $49.2 |
| Production materials, stores and supplies | 27.5 | 25.0 |
| Finished and in-process goods | 141.6 | 157.4 |
| Subtotal | $214.8 | $231.6 |
| Less: LIFO reserve | (28.8) | (35.7) |
| Inventories, net | $186.0 | $195.9 |
As of December 31, 2025, approximately 34 percent,15 percent, and 51 percent of our Inventories, net, were accounted for under the FIFO, average cost, and LIFO methods, respectively. As of December 31, 2024, approximately 28 percent,13 percent, and 59 percent of our Inventories, net, were accounted for under the FIFO, average cost, and LIFO methods, respectively. The repositioning actions taken to improve our Performance Chemicals reportable segment has reduced overall LIFO inventory (refer to Note 15 for more detail).
During the years ended December 31, 2025 and 2024, changes to inventory quantities carried on a LIFO basis, resulted in a pre-tax increase of $10.0 million and pre-tax decrease of $6.3 million for the years ended December 31, 2025 and 2024, respectively, recorded in Cost of sales on our consolidated statement of operations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.